Generic ADP-binding proteins

Generic ADP-binding proteins represent a diverse functional class of proteins that interact with adenosine diphosphate (ADP) to mediate various physiological processes. This group includes the P2Y family of G protein-coupled receptors, such as P2Y12, which is a primary target for antiplatelet therapy in cardiovascular disease (Source: StatPearls, P2Y12 Inhibitors). It also encompasses the Poly (ADP-ribose) polymerase (PARP) family, which is essential for DNA repair and serves as a target for oncology drugs like olaparib (Source: PubMed, PMID: 23001106). Furthermore, mitochondrial ADP/ATP translocases (ANT) belong to this category, facilitating the exchange of ADP and ATP to maintain cellular energy homeostasis (Source: UniProt, P02708). Because the term Generic ADP-binding proteins covers multiple distinct protein families with unrelated structures and functions, it is considered a broad classification rather than a specific therapeutic target. Therapeutic intervention is always directed at specific members within this class to achieve selective pharmacological effects. Drugs targeting these proteins are critical in managing conditions ranging from acute coronary syndromes to hereditary cancers.

Other names

ADP-binding proteinsAdenosine diphosphate binding proteins

Pharmacological agents typically target specific members of this class, acting as antagonists of purinergic receptors (e.g., P2Y12) to inhibit platelet aggregation or as inhibitors of enzymes (e.g., PARP) to prevent DNA repair in malignant cells.